Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Mesoblast Limited — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.83 (market cap $5.86B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 3.3× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 7,780,002). Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 61 Days and Mesoblast Limited for 15 Days on average.
| JNK | MESO | |
|---|---|---|
Market Cap | $5.86B | $1.75B |
Volume | 7,780,002 | 239,027 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $20.96 |
52-Week Low | $92.30 | $13.19 |
Typical Hold Time | 61 Days | 15 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK, a high-yield bond ETF, trades at $92.83, up 0.08% on the day, amid a bearish technical signal from moving averages. The fund maintains a consistent dividend payout, with recent distributions of $0.53. Market sentiment is influenced by rising bond yields and geopolitical tensions, as highlighted in recent financial news.
The outlook for JNK is challenged by high interest rates and inflation concerns, which pressure junk bond valuations. Opportunities exist for income-focused investors due to the ETF's yield, but risks include further yield spikes and economic slowdowns affecting credit quality.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
